Meyka Pro banner
ZimVie Inc.

ZimVie Inc. (NASDAQ: ZIMV) Stock Competitors & Peer Comparison

See ZIMV's competitors and their performance on the NASDAQ and across the wider stock market.

ZIMVNASDAQ
HealthcareMedical - Devices
$18.99
$0.00(0.00%)
U.S. Market opens in 3h 55m

Peer Comparison Table: Medical - Devices Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for ZIMV and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ZIMV$18.99+0.00%535.6M-27.52-$0.69N/A
ABT$109.72+1.01%189.9B21.06$5.21+2.26%
BSX-PA$122.18+2.37%175.4B230.53$0.53N/A
SYK$348.15+0.68%133.4B25.99$13.39+1.00%
MDT$90.68+1.42%116B16.39$5.53+3.15%
BSX$51.19+1.45%76.1B16.51$3.10N/A
EW$93.66+1.77%53.9B34.69$2.70N/A
DXCM$89.53+2.14%33.8B38.42$2.33N/A
RMD$224.84+2.18%32.6B20.87$10.77+1.07%
PHG$27.05+0.41%26.4B15.46$1.75+3.65%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Abbott Laboratories (NYSE: ABT)

ZIMV vs ABT Comparison August 2026

ZimVie Inc. (NASDAQ: ZIMV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZIMV stands at 535.6M. In comparison, ABT has a market cap of 189.9B. Regarding current trading prices, ZIMV is priced at $18.99 on the NASDAQ, while ABT trades at $109.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZIMV currently has a P/E ratio of -27.52, whereas ABT's P/E ratio is 21.06. In terms of profitability, ZIMV's ROE is -0.01%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ZIMV is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for ZIMV.Check ABT's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions